Browse the evidence

GLP-1 Receptor Agonists (specifically Semaglutide) induce significant weight loss (10-15%) and improve metabolic and endocrine markers (including menstrual regularity and insulin sensitivity) in women with PCOS, although long-term sustainability requires continued treatment.

Semaglutide (a GLP-1 RA) is an effective treatment for women with PCOS who are obese and haven't succeeded with lifestyle changes alone. It promotes significant weight loss (approx. 11-15 kg) and can restore menstrual regularity and improve insulin sensitivity. However, stopping the medication often leads to partial weight regain, suggesting it may need to be a long-term therapy for sustained benefits.

Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, produces superior mean weight loss (up to 24.2%) and metabolic improvements compared to placebo and existing dual agonists in phase 2 trials for obesity and type 2 diabetes.

Retatrutide is a once-weekly injection that targets three hormones to significantly reduce body weight and improve blood sugar control. In clinical trials, it led to an average 24% weight loss in people with obesity over 48 weeks. Common side effects like nausea are manageable with dose titration. It is currently in phase 3 trials for broader approval.

Tirzepatide induces significant weight reduction in individuals with obesity caused by pathogenic MC4R mutations, achieving efficacy comparable to non-carriers.

If you have obesity caused by an MC4R mutation, tirzepatide is a highly effective treatment option. Clinical data shows you will likely lose a significant amount of weight (around 18%) over 72 weeks, similar to people without this genetic mutation. Because lifestyle changes alone are often insufficient for this specific genetic profile, pharmacological intervention with tirzepatide is recommended to manage severe obesity and its complications.

Carrying the T allele of the GLP1R missense variant rs10305420 (p.Pro7Leu) significantly increases weight loss efficacy in patients treated with GLP-1 receptor agonists, adding approximately 0.76 kg of weight loss per allele copy.

If you are taking a GLP-1 medication like semaglutide or tirzepatide, your genetics play a role in how much weight you lose. Specifically, a common genetic variant (rs10305420) is linked to better weight loss results. While this genetic effect is modest (adding less than 1 kg on average), it is a real biological factor. This suggests that genetic testing could eventually help doctors predict who will respond best to which drug, allowing for more personalized treatment plans rather than a one-size-fits-all approach.

Once-weekly efpeglenatide significantly reduces HbA1c and body weight in patients with type 2 diabetes and obesity, with a safety profile characterized by mild-to-moderate gastrointestinal side effects and low hypoglycemia risk.

Efpeglenatide is a once-weekly (or monthly) injection that helps lower blood sugar and lose weight in people with type 2 diabetes and obesity. It is generally well-tolerated, with common side effects like nausea being mild and temporary. It offers a convenient alternative to daily medications and has cardiovascular benefits for high-risk patients.

Anti-obesity medications (AOMs), particularly GLP-1 and dual GIP/GLP-1 agonists, produce significant weight loss (5-20%+) and should be continued long-term as disease-modifying agents rather than short-term aids.

If you have obesity or overweight with related health issues, talk to your doctor about long-term medication options like GLP-1 agonists. These are not quick fixes but chronic disease treatments. Expect to start with a low dose to minimize stomach issues and increase it slowly. You must combine this with lifestyle changes for the best results, and do not stop the medication once you reach your goal, as stopping often leads to regaining the weight.

Higher protein intake (≥25% TDE or ≥1.25 g/kg/day) during energy restriction promotes greater fat loss and fat-free mass preservation compared to standard protein intakes, with modest but clinically relevant long-term weight maintenance benefits.

To maximize fat loss and preserve muscle while dieting, aim for at least 1.25 grams of protein per kilogram of body weight daily, or roughly 25% of your total calories from protein. This approach helps you feel fuller longer and burns slightly more calories through digestion, leading to better fat loss and muscle retention than standard protein intakes.

GLP-1 receptor agonists (GLP-1RAs) and sodium-glucose co-transporter-2 inhibitors (SGLT2-is) significantly improve hepatic steatosis and steatohepatitis in patients with MASLD, primarily through weight loss and glycemic control, with some agents also demonstrating antifibrotic properties.

If you have fatty liver disease (MASLD), especially if you also have type 2 diabetes or obesity, GLP-1 receptor agonists (like semaglutide or liraglutide) and SGLT2 inhibitors (like empagliflozin or dapagliflozin) are currently the most effective and accessible pharmaceutical options. They work by improving insulin sensitivity, promoting weight loss, and directly reducing liver fat and inflammation. While they may require injections (for GLP-1RAs) and can cause mild stomach upset, their benefits for both liver and heart health make them a cornerstone of treatment. Always consult your doctor to determine the best option for your specific health profile.

Resistance exercise is the most effective lifestyle intervention for increasing muscle strength in people with type 2 diabetes (T2D), although it may induce an anabolic resistance regarding muscle mass gains compared to healthy controls.

For people with Type 2 Diabetes, resistance training is the best way to build strength. While it might not build as much muscle mass as it does in healthy people (due to 'anabolic resistance'), it is still superior to aerobic exercise for strength. Aim for at least two days a week of resistance training, potentially starting with home-based programs if gym access is a barrier.

Pharmacotherapies for T2D and obesity, specifically GLP-1 receptor agonists (e.g., Tirzepatide) and SGLT2 inhibitors, cause significant loss of lean body mass (20-50% of total weight loss), necessitating concurrent resistance exercise and protein intake to mitigate muscle loss.

If you are taking GLP-1 or SGLT2 medications for diabetes or weight loss, expect to lose some muscle along with fat (up to 50% of the weight). To protect your metabolism and strength, you must combine these medications with resistance exercise and adequate protein intake, as the drugs themselves do not preserve muscle.

Unimolecular GLP1R/GIPR dual agonists (e.g., tirzepatide) produce superior body weight reduction and glycemic improvements compared to GLP-1 receptor agonists alone, driven by GIP receptor signaling in central nervous system GABAergic neurons.

If you are managing obesity or Type 2 Diabetes, dual-acting medications (like tirzepatide) that target both GLP-1 and GIP receptors have shown superior weight loss (up to 20-22%) compared to GLP-1 only drugs. These are taken once weekly. Discuss with your doctor if this option is suitable, noting it may help mitigate some nausea associated with GLP-1 only treatments.

Treatment with semaglutide 2.4 mg for 12 months significantly reduces body weight and improves cardiometabolic risk factors (blood pressure, lipids, HbA1c) in adults with obesity or overweight compared to no obesity medication treatment.

If you have obesity or overweight with related health issues, semaglutide 2.4 mg taken once weekly for a year can lead to significant weight loss (around 15%) and improvements in blood pressure, cholesterol, and blood sugar compared to not using obesity medication. It requires a gradual dose increase to 2.4 mg and should be combined with diet and exercise.

Tirzepatide 15 mg administered once weekly for 72 weeks is the most cost-efficient intervention for achieving high-magnitude weight loss targets (15% and 20%) in adults with obesity, yielding a cost per kilogram of weight loss of £89.24.

For adults with obesity seeking significant weight loss, the 15mg weekly dose of tirzepatide, combined with diet and exercise, offers the best value for achieving major weight reduction goals (15-20%) over 72 weeks, despite higher initial drug costs, due to superior efficacy and potential long-term healthcare savings.

Tirzepatide 10 mg is the most cost-efficient dose for achieving moderate weight loss targets (10% and 15%) and provides competitive outcomes for BMI improvement compared to 5mg and 15mg doses.

For patients targeting moderate weight loss (10-15%), the 10mg weekly dose of tirzepatide offers a strong balance of efficacy and cost-efficiency, often outperforming lower doses and competing well with higher doses for BMI improvements.

Newer anti-obesity medications (GLP-1 and GLP-1/GIP agonists like semaglutide and tirzepatide) produce significantly greater weight loss (15-22.5%) compared to lifestyle modifications alone, which typically yield modest and unsustainable results.

Newer GLP-1 and GLP-1/GIP medications (like semaglutide and tirzepatide) are significantly more effective for weight loss (15-22.5%) than lifestyle changes alone. However, access is difficult due to insurance coverage, supply shortages, and cost. These medications should be viewed as a tool to help manage obesity as a chronic disease, but they still require lifestyle support and are not a 'magic pill' without side effects or administrative burdens.

GLP-1 receptor agonists (semaglutide and tirzepatide) are effective treatments for weight regain after bariatric surgery, producing clinically significant weight loss without severe adverse events.

If you regain weight after sleeve gastrectomy, GLP-1 medications like semaglutide or tirzepatide are effective and safe options to help you lose it back, avoiding the need for high-risk revisional surgery.

Tirzepatide (15 mg once weekly) combined with lifestyle counseling produces a mean weight loss of 20.9% over 72 weeks in patients with obesity or overweight.

If you are prescribed Tirzepatide (Zepbound), expect to take a 15 mg injection once weekly. This works best when combined with a 500 kcal daily caloric deficit, physical activity, and lifestyle counseling. Be prepared for potential gastrointestinal side effects like nausea, which can often be managed by eating smaller meals.

Semaglutide (2.4 mg once weekly) produces a mean weight loss of 14.9% over 68 weeks in patients with obesity without diabetes.

If you are prescribed Semaglutide (Wegovy), expect to take a 2.4 mg injection once weekly. This can lead to a 14.9% reduction in body weight over 68 weeks. Be prepared for potential gastrointestinal side effects like nausea, which can often be managed by eating smaller meals.

Liraglutide (3 mg once daily) produces a mean weight loss of 8% over 56 weeks in patients without diabetes.

If you are prescribed Liraglutide (Saxenda), expect to take a 3 mg injection once daily. This can lead to an 8% reduction in body weight over 56 weeks. Be prepared for potential gastrointestinal side effects like nausea, which can often be managed by eating smaller meals.

Subcutaneous semaglutide (up to 1.0 mg once-weekly) produces significantly greater reductions in BMI and waist circumference compared to liraglutide (up to 3.0 mg once-daily) in obese patients with type 2 diabetes over a 12-month period, while both agents significantly lower HbA1c.

For obese patients with type 2 diabetes, switching from or choosing semaglutide over liraglutide is likely to result in greater weight loss and waist circumference reduction. While both drugs effectively lower blood sugar, semaglutide offers superior body composition benefits. Patients should be aware that gastrointestinal side effects are common, especially with semaglutide, but these often subside as the dose is titrated up.

Obesity pharmacotherapy (GLP-1/GIP agonists) reduces body weight with minimal loss of lean mass and improves cardiovascular outcomes, potentially mitigating the adverse effects of intermittent fasting.

If you are considering obesity pharmacotherapy (like GLP-1 agonists), know that it can lead to significant weight loss (up to 21% in some trials) with minimal loss of muscle mass, which is a key advantage over intermittent fasting. It also reduces cardiovascular risk. However, long-term safety is still being studied, and combining it with lifestyle changes (diet and exercise) is recommended for the best outcomes.

Dual GLP-1/GIP receptor agonists (e.g., tirzepatide) achieve weight loss magnitudes (15-20%) comparable to bariatric surgery, significantly outperforming older pharmacotherapies and single-agonist GLP-1s.

If you have obesity, newer dual-agonist medications (like tirzepatide) are currently the most effective non-surgical treatment available, offering weight loss results similar to bariatric surgery. They work by targeting multiple hormonal pathways to reduce appetite and improve metabolism. Consult a doctor to see if you qualify based on your BMI and comorbidities.

Retatrutide, a triple agonist of GLP-1, GIP, and glucagon receptors, produces significant, dose-dependent reductions in body weight, BMI, and metabolic markers in obese adults with or without type 2 diabetes.

Retatrutide is a weekly injection that significantly reduces body weight (average ~14%) and improves metabolic health in obese adults, including those with type 2 diabetes. It works by targeting three hormone receptors (GLP-1, GIP, glucagon) to reduce appetite and improve insulin sensitivity. Higher doses (8-12 mg) generally produce greater weight loss. Common side effects include nausea and vomiting, which are often manageable. It is a prescription medication requiring medical supervision.

Weekly subcutaneous VK2735, a GIP/GLP-1 receptor dual agonist, produces significant, dose-dependent weight loss in adults with obesity or overweight (≥1 comorbidity) over 13 weeks, with the 15 mg dose achieving a mean 14.7% reduction.

Take VK2735 once weekly as prescribed. Start with the lowest dose (2.5 mg) and follow the titration schedule to minimize side effects. Combine with a 500 kcal daily caloric deficit and 150 minutes of exercise per week for best results. Expect significant weight loss (up to 14.7% at 15 mg) within 13 weeks, with side effects like nausea typically subsiding after the titration phase.